Future therapeutic perspectives for tension-type headache

Marc E Lenaerts

Research output: Contribution to journal › Article

Abstract

The therapy for tension-type headache remains insufficient, and recent advances have been scarce. Although tricyclic antidepressants are at the forefront of treatment advances, upcoming agents tentatively modifying central sensitization are promising. Botulinum toxin failed to meet expectations. This article reviews current treatments, emphasizing newer approaches. Much remains to be achieved.

Original languageEnglish (US)
Pages (from-to)461-464
Number of pages4
JournalCurrent Pain and Headache Reports
Volume11
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

Central Nervous System Sensitization
Tension-Type Headache
Botulinum Toxins
Tricyclic Antidepressive Agents
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Future therapeutic perspectives for tension-type headache. / Lenaerts, Marc E.

In: Current Pain and Headache Reports, Vol. 11, No. 6, 12.2007, p. 461-464.

Research output: Contribution to journal › Article

Lenaerts, ME 2007, 'Future therapeutic perspectives for tension-type headache', Current Pain and Headache Reports, vol. 11, no. 6, pp. 461-464. https://doi.org/10.1007/s11916-007-0234-0
Lenaerts ME. Future therapeutic perspectives for tension-type headache. Current Pain and Headache Reports. 2007 Dec;11(6):461-464. https://doi.org/10.1007/s11916-007-0234-0
Lenaerts, Marc E. / Future therapeutic perspectives for tension-type headache. In: Current Pain and Headache Reports. 2007 ; Vol. 11, No. 6. pp. 461-464.
@article{6c04feb9d8d448c58e14d65e9a1e9074,
title = "Future therapeutic perspectives for tension-type headache",
abstract = "The therapy for tension-type headache remains insufficient, and recent advances have been scarce. Although tricyclic antidepressants are at the forefront of treatment advances, upcoming agents tentatively modifying central sensitization are promising. Botulinum toxin failed to meet expectations. This article reviews current treatments, emphasizing newer approaches. Much remains to be achieved.",
author = "Lenaerts, {Marc E}",
year = "2007",
month = "12",
doi = "10.1007/s11916-007-0234-0",
language = "English (US)",
volume = "11",
pages = "461--464",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Future therapeutic perspectives for tension-type headache

AU - Lenaerts, Marc E

PY - 2007/12

Y1 - 2007/12

N2 - The therapy for tension-type headache remains insufficient, and recent advances have been scarce. Although tricyclic antidepressants are at the forefront of treatment advances, upcoming agents tentatively modifying central sensitization are promising. Botulinum toxin failed to meet expectations. This article reviews current treatments, emphasizing newer approaches. Much remains to be achieved.

AB - The therapy for tension-type headache remains insufficient, and recent advances have been scarce. Although tricyclic antidepressants are at the forefront of treatment advances, upcoming agents tentatively modifying central sensitization are promising. Botulinum toxin failed to meet expectations. This article reviews current treatments, emphasizing newer approaches. Much remains to be achieved.

UR - http://www.scopus.com/inward/record.url?scp=36849034338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849034338&partnerID=8YFLogxK

U2 - 10.1007/s11916-007-0234-0

DO - 10.1007/s11916-007-0234-0

M3 - Article

VL - 11

SP - 461

EP - 464

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 6

ER -

Access to Document